Navigation Links
Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore
Date:1/19/2009

COLUMBUS, Ohio, Jan. 19 /PRNewswire-FirstCall/ -- Abbott Nutrition today announced that it is initiating a precautionary, voluntary recall of ZonePerfect(R) Chocolate Peanut Butter bars, ZonePerfect(R) Peanut Toffee bars and NutriPals(TM) Peanut Butter Chocolate bars in response to the widening recall involving peanut butter and peanut paste ingredients manufactured by Peanut Corporation of America (PCA). PCA was one of the peanut ingredient suppliers to the company.

The specified Abbott Nutrition items, sold in the U.S. and internationally (Mexico, New Zealand and Singapore) in various packages and quantities, have not been linked to a nationwide salmonella outbreak and there have been no reported cases of the salmonella illness associated with ZonePerfect or NutriPals products. Abbott Nutrition tests every lot of finished ZonePerfect and NutriPals bars for salmonella and no salmonella contamination has been detected. This voluntary recall does not apply to Abbott Nutrition products sold in Canada.

Abbott Nutrition's action to issue a voluntary recall was supported by the U.S. Food & Drug Administration's advisement to manufacturers of an ongoing outbreak of salmonella involving peanut butter and peanut paste supplied by PCA. No other Abbott Nutrition products have been impacted by the PCA recall.

As part of its priority to ensure the safety and quality of all of its products, Abbott is issuing the voluntary recall. Abbott is working with retail partners to remove the specified products from retail store shelves and encouraging customers and consumers to verify if they have the specified products.

Consumers who have purchased the recalled products are urged to destroy the product. U.S. consumers with questions or who would like a refund may contact Abbott Nutrition Consumer Relations at (800) 986-8884, Monday through Friday, between the hours of 8:30 a.m. and 5:00 p.m. Eastern Time. Consumers with questions or concerns about their health should contact their doctor.

    Products impacted by the voluntary withdrawal are as follows:

    * ZonePerfect Chocolate Peanut Butter bars, all sizes and quantities
    * ZonePerfect Peanut Toffee bars, all sizes and quantities
    * NutriPals Peanut Butter Chocolate nutrition bars, all sizes and
      quantities


    For images of these products, please visit the following link:

   http://abbottnutrition.com/pdf/peanut.pdf

Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. For more information on Salmonella, please visit the Centers for Disease Control and Prevention's Website at http://www.cdc.gov.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area ... fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. ... in Plastic and Reconstructive Surgery. The candidate will have the opportunity to ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The experts have ... are we supposed to get things done in a healthy way these days? FlexiSpot, ... launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon ... reform plan, has announced his candidacy for the 52nd Congressional District currently held by ... America’s Promise. Coming to this country at age eleven after suffering homelessness and hardship ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: